Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371527 | 0.93 | MET (0.59) | METKDRAXLPDGFRA | |
| SCHEMBL377200 | 0.93 | MET (0.59) | METKDRAXLPDGFRA | |
| SCHEMBL371643 | 0.87 | MET (0.61) | METKDRAXLPDGFRA | |
| SCHEMBL12443878 | 0.87 | MET (0.52) | METKDRAXL | |
| SCHEMBL4991680 | 0.86 | MET (0.54) | METKDRAXL | |
| SCHEMBL371617 | 0.81 | MET (0.57) | METKDRAXLPDGFRA | |
| SCHEMBL19711760 | 0.81 | MET (0.57) | METKDRAXLPDGFRA | |
| SCHEMBL374015 | 0.80 | MET (0.68) | METKDRAXLPDGFRA | |
| SCHEMBL374016 | 0.79 | MET (0.56) | METKDRAXL | |
| SCHEMBL15338415 | 0.78 | MET (0.49) | METKDRAXLPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2392565-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |